Otamixaban clinical trials

Stable chronic renal impairment as defined by Cockcroft-Gault formula, Vital signs, cardiac function and laboratory parameters within the acceptable range. If female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal. Exclusion criteria: Uncontrolled clinically relevant cardiovascular, pulmonary, gastro-intestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic if female or infectious disease, or signs of acute illness.

Active hepatitis, hepatic insufficiency. Acute renal failure, nephrotic syndrome. History of or current hematuria of urologic origin. Subject requiring dialysis during the study. History or presence of drug or alcohol abuse within two years before inclusion.

Smoking more than 15 cigarettes or equivalent per day. Any significant change in chronic treatment medication within days before inclusion. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.

More Information. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Allergy to otamixaban. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.

Am Heart J. Epub Nov 7. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. Epub Jan Circ Cardiovasc Interv. National Library of Medicine U.

National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Acute Coronary Syndrome. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Triple Participant, Investigator, Outcomes Assessor.

Coronary Disease. Phase 2. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :.

Actual Study Completion Date :. Experimental: Otamixaban Dose 1 dosage regimen 1. Drug: Otamixaban XRP intravenous administration. Experimental: Otamixaban Dose 2 dosage regimen 2. Experimental: Otamixaban Dose 3 dosage regimen 3. Experimental: Otamixaban Dose 4 dosage regimen 4. Experimental: Otamixaban Dose 5 dosage regimen 5. Drug: unfractionated heparin intravenous administration Drug: eptifibatide intravenous administration.

April 24, Key Record Dates.